A Multi-center, Randomized, Open-label and Positive Controlled Phase II Clinical Trial to Assess Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Patients With Chronic Hepatitis B.
Phase of Trial: Phase II
Latest Information Update: 23 Apr 2013
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Peginterferon alfa-2a
- Indications Hepatitis B
- Focus Therapeutic Use
- 01 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Jan 2012 Actual patient number is 205 according to ClinicalTrials.gov.
- 30 Jan 2012 Planned end date changed from 1 Mar 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov.